209 related articles for article (PubMed ID: 23079060)
1. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.
Parikh AR; Olnes MJ; Barrett AJ
Semin Hematol; 2012 Oct; 49(4):304-11. PubMed ID: 23079060
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.
Barrett AJ; Sloand EM
Curr Hematol Malig Rep; 2008 Jan; 3(1):23-8. PubMed ID: 20425443
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
Sloand EM; Wu CO; Greenberg P; Young N; Barrett J
J Clin Oncol; 2008 May; 26(15):2505-11. PubMed ID: 18413642
[TBL] [Abstract][Full Text] [Related]
4. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults.
Zhu X; Guan J; Xu J; Wei J; Jiang L; Yin J; Zhao L; Zhang Y
Blood Cells Mol Dis; 2014 Sep; 53(3):157-60. PubMed ID: 24931461
[TBL] [Abstract][Full Text] [Related]
5. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
6. Targeting immune dysregulation in myelodysplastic syndromes.
Olnes MJ; Sloand EM
JAMA; 2011 Feb; 305(8):814-9. PubMed ID: 21343581
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.
Sloand EM; Olnes MJ; Shenoy A; Weinstein B; Boss C; Loeliger K; Wu CO; More K; Barrett AJ; Scheinberg P; Young NS
J Clin Oncol; 2010 Dec; 28(35):5166-73. PubMed ID: 21041705
[TBL] [Abstract][Full Text] [Related]
8. Management of the refractory aplastic anemia patient: what are the options?
Marsh JC; Kulasekararaj AG
Hematology Am Soc Hematol Educ Program; 2013; 2013():87-94. PubMed ID: 24319168
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.
Scheinberg P; Wu CO; Nunez O; Young NS
J Pediatr; 2008 Dec; 153(6):814-9. PubMed ID: 18672253
[TBL] [Abstract][Full Text] [Related]
10. [Combination of rabbit antithymocyte globulin plus cyclosporin A as first-line immunosuppressive therapy for the childhood with severe aplastic anemia.].
Liu LY; Wang HJ; Zhang L; Jing LP; Zhou K; Yang DL; Li HQ; Liu QG; Yan ZS; Liu YZ; Wu YH; Chu YL; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2009 Nov; 30(11):749-53. PubMed ID: 20137310
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.
Aggarwal N; Manley AL; Shalhoub R; Durrani J; Rios O; Lotter J; Patel BA; Wu CO; Young NS; Groarke EM
Am J Hematol; 2023 Jun; 98(6):932-939. PubMed ID: 37021397
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome.
Biesma DH; van den Tweel JG; Verdonck LF
Cancer; 1997 Apr; 79(8):1548-51. PubMed ID: 9118037
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C; Braun T; Arana R; Marceau-Renaut A; Lazarian G; Soret J; Cereja S; Letestu R; Eclache V; Lusina D; Baran-Marszak F; Ades L; Preudhomme C; Martin A; Fenaux P; Gardin C
Leuk Res; 2018 Aug; 71():67-74. PubMed ID: 30025278
[TBL] [Abstract][Full Text] [Related]
15. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A.
Goldenberg NA; Graham DK; Liang X; Hays T
Pediatr Blood Cancer; 2004 Dec; 43(7):718-22. PubMed ID: 15390303
[TBL] [Abstract][Full Text] [Related]
17. [Immunosuppressive therapy using antithymocyte globulin and cyclosporin A with or without human granulocyte colony-stimulating factor in children with acquired severe aplastic anemia].
Liu X; Zou Y; Wang S; Zhang L; Yang W; Zhang J; Liu F; Liu T; Chen X; Ruan M; Zhou J; Cai X; Qi B; Chang L; An W; Guo Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):84-9. PubMed ID: 24739716
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study.
Shin SH; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
Ann Hematol; 2013 Jun; 92(6):817-24. PubMed ID: 23318980
[TBL] [Abstract][Full Text] [Related]
19. The role of the immune system in myelodysplasia: implications for therapy.
Sloand EM; Rezvani K
Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
[TBL] [Abstract][Full Text] [Related]
20. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.
Scheinberg P; Nunez O; Weinstein B; Scheinberg P; Wu CO; Young NS
Blood; 2012 Jan; 119(2):345-54. PubMed ID: 22067384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
